Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | FABP1 | P07148 | 1/20 | 0.85 |
| ▸ | THRB | P10828 | 1/20 | 0.85 |
| ▸ | LIFR | P42702 | 1/20 | 0.85 |
| ▸ | RECQL | P46063 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491490 | 1.00 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29354246 | 0.92 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 0.92 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29459634 | 0.92 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996233 | 0.92 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL14601398 | 0.87 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL13805380 | 0.87 | NR1H4 (0.79) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL12932245 | 0.86 | NR1H4 (0.81) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL21624441 | 0.86 | NR1H4 (1.00) | NR1H4LIFR | |
| SCHEMBL16917074 | 0.86 | NR1H4 (0.77) | NR1H4MEN1FABP1THRBLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379081-B1 | TREATMENT OF DIARRHOEA | ROYAL COLLEGE OF SURGEONS IE (IE) | 2013-03-20 | — | — | EP | claimed |
| EP-2379081-A1 | TREATMENT OF DIARRHOEA | Royal College of Surgeons in Ireland (IE) | 2011-10-26 | — | — | EP | claimed |
| US-20110257139-A1 | TREATMENT OF DIARRHOEA | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2011-10-20 | — | — | US | claimed |
| WO-2010069604-A1 | TREATMENT OF DIARRHOEA | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2010-06-24 | — | — | WO | claimed |
| EP-1140079-B1 | ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-6984650-B2 | Use of FXR ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2006-01-10 | — | — | US | disclosed |
| EP-1140079-A4 | ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS | GLAXO GROUP LTD (GB) | 2004-06-09 | — | — | EP | disclosed |
| US-20040048316-A1 | Assays for ligands for nuclear receptors | HAFFNER CURT DALE (US) | 2004-03-11 | — | — | US | disclosed |
| US-6639078-B1 | Assays for ligands for nuclear receptors | SMITHKLINE BEECHAM CORPORATION | 2003-10-28 | — | — | US | disclosed |
| EP-1140079-A1 | ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS | GLAXO GROUP LIMITED (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037077-A1 | ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS | GLAXO GROUP LIMITED (GB) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048316-A1 | Assays for ligands for nuclear receptors | NCOA1, NCOA3, NCOR1 | NR1H4 22/4885MEN1 4124/4885FABP1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.